Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

[1]  D. Bauer,et al.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism , 2009 .

[2]  J. Holst,et al.  Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. , 2007, Bone.

[3]  Farshid Guilak,et al.  Circadian Oscillation of Gene Expression in Murine Calvarial Bone , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  L. Saba,et al.  Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. , 2007, The Journal of clinical endocrinology and metabolism.

[5]  W. Fraser,et al.  The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  C. Dunstan,et al.  RANK ligand. , 2007, The international journal of biochemistry & cell biology.

[7]  D. Generali,et al.  The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. , 2007, Bone.

[8]  Y. Kadono,et al.  Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.

[9]  R. Eastell,et al.  Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. , 2005, The Journal of clinical endocrinology and metabolism.

[10]  D. Henriksen.  The gut feeling of bone remodeling , 2005 .

[11]  G. Mazzoccoli,et al.  Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  E. Wagner,et al.  The Molecular Clock Mediates Leptin-Regulated Bone Formation , 2005, Cell.

[13]  A. Angeli,et al.  Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? , 2005, Journal of endocrinological investigation.

[14]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[15]  L. Hofbauer,et al.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.

[16]  W. Fraser,et al.  Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. , 2003, Clinical chemistry.

[17]  A. Angeli,et al.  Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  W. Fraser,et al.  Parathyroid hormone secretory pattern, circulating activity, and effect on bone turnover in adult growth hormone deficiency. , 2003, Bone.

[19]  W. Woloszczuk,et al.  Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. , 2003, Clinical laboratory.

[20]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[21]  S. Mohan,et al.  A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. , 2002, Bone.

[22]  Colin R Dunstan,et al.  Serum osteoprotegerin levels in healthy controls and cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.

[24]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[25]  R. Eastell,et al.  Measurement of Osteocalcin , 2000, Annals of clinical biochemistry.

[26]  S. Mochizuki,et al.  Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. , 1998, Biochemical and biophysical research communications.

[27]  M. Burritt,et al.  Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  S B Rosalki,et al.  BIOCHEMICAL MARKERS OF BONE TURNOVER , 1998, International journal of clinical practice.

[29]  R. Parker,et al.  Diurnal Variation of Bone Mineral Turnover in Elderly Men and Women , 1997, Calcified Tissue International.

[30]  J. Kanis.  Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism , 1994 .

[31]  P. Delmas,et al.  Biochemical markers of bone turnover , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.